Germline variants in CDKN2A wild‐type melanoma prone families
Molecular Oncology · 2025
DOI: 10.1002/1878-0261.70020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Gjertrud T Iversen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Science, K.G. Jebsen Center for Genome-Directed Cancer Therapy, University of Bergen, Bergen, Norway. Hauptthemen laut MEDLINE: Melanoma, Germ-Line Mutation, Genetic Predisposition to Disease, Cyclin-Dependent Kinase Inhibitor p16. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kreftforeningen, Bodil and Magnes Cancer Research Foundation, Oslo.
Abstract (Originalsprache)
Germline pathogenic variants in CDKN2A are well established as an underlying cause of familial malignant melanoma. While pathogenic variants in other genes have also been linked to melanoma, most familial cases remain unexplained. We assessed pathogenic germline variants in 360 cancer‐related genes in 56 Norwegian melanoma‐prone families. The index cases were selected based on familial history of melanoma and/or multiple primary melanomas, along with previous negative tests for pathogenic CDKN2A variants. We found 6 out of 56 index individuals to carry germline pathogenic or likely pathogenic variants in BRCA2 , MRE11 , ATM , MSH2 , CHEK2 , and AR . One family member with melanoma (not index case) carried a pathogenic variant in MAP3K6 . In addition, we found a high fraction of variants previously considered benign and/or as variants of uncertain significance in xeroderma pigmentosum‐related genes. In particular, XPC L48F was found in 8 indexes; thus, the allele fraction (0.07) was significantly higher than in comparable healthy populations (0.02–0.03; P ‐values from 0.007 to 0.014). In conclusion, we found that several melanoma‐prone families have pathogenic variants in genes not usually linked to melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Science, K.G. Jebsen Center for Genome-Directed Cancer Therapy, University of Bergen, Bergen, Norway.
- Department of Oncology, Haukeland University Hospital, Bergen, Norway.
- Department of Oncology, Akershus University Hospital, Lørenskog, Norway.
- Institute of Clinical Medicine, University of Oslo, Norway.
ORCID-Profile: Jürgen Geisler, Stian Knappskog
Förderung
- Kreftforeningen
- Bodil and Magnes Cancer Research Foundation, Oslo
Zitieren
APA
Iversen, G. T., Loeng, M., Holth, A. L., Lønning, P. E., Geisler, J., & Knappskog, S. (2025). Germline variants in CDKN2A wild‐type melanoma prone families. Molecular Oncology. https://doi.org/10.1002/1878-0261.70020
Vancouver
Iversen GT, Loeng M, Holth AL, Lønning PE, Geisler J, Knappskog S. Germline variants in CDKN2A wild‐type melanoma prone families. Molecular Oncology. 2025. doi:10.1002/1878-0261.70020
BibTeX
@article{Iversen2025,
author = {Iversen, Gjertrud T and Loeng, Marie and Holth, Amalie Lund and Lønning, Per E and Geisler, Jürgen and Knappskog, Stian},
title = {Germline variants in CDKN2A wild‐type melanoma prone families},
journal = {Molecular Oncology},
year = {2025},
doi = {10.1002/1878-0261.70020}
}
EUVIMED